Advertisement

Topics

Erlotinib indication modified by FDA to limit use to specific mutations

10:02 EDT 19 Oct 2016 | ecancermedicalscience

On October 18, 2016, the U.S. Food and Drug Administration modified the indication for erlotinib (TARCEVA, Astellas Pharm Global Development Inc.) for treatment of non-small cell lung cancer (NSCLC) to limit use to patients whose tumours have specific...

Original Article: Erlotinib indication modified by FDA to limit use to specific mutations

NEXT ARTICLE

More From BioPortfolio on "Erlotinib indication modified by FDA to limit use to specific mutations"

Quick Search
Advertisement
 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...